华海药业
(600521)
| 流通市值：266.36亿 | | | 总市值：266.36亿 |
| 流通股本：14.97亿 | | | 总股本：14.97亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,408,881,906.05 | 4,516,353,788.97 | 2,368,563,881.42 | 9,547,425,412.4 |
| 营业收入 | 6,408,881,906.05 | 4,516,353,788.97 | 2,368,563,881.42 | 9,547,425,412.4 |
| 二、营业总成本 | 5,972,319,712.38 | 4,001,688,219.95 | 2,002,446,656.2 | 7,978,739,192.17 |
| 营业成本 | 2,454,250,665.3 | 1,656,534,959.61 | 834,236,299.54 | 3,636,604,438.41 |
| 税金及附加 | 88,448,434.47 | 58,902,417.86 | 32,446,838.68 | 116,829,397.55 |
| 销售费用 | 1,288,862,031.04 | 945,364,975.35 | 515,002,998.6 | 1,678,900,157.74 |
| 管理费用 | 1,143,453,880.19 | 720,107,570.65 | 334,379,521.12 | 1,464,239,757.56 |
| 研发费用 | 829,481,556.27 | 523,190,387.71 | 238,907,980.88 | 986,685,361.64 |
| 财务费用 | 167,823,145.11 | 97,587,908.77 | 47,473,017.38 | 95,480,079.27 |
| 其中:利息费用 | 175,541,052.72 | 116,299,888.03 | 56,895,226.12 | 219,800,151.74 |
| 其中:利息收入 | 20,318,023.01 | 14,521,370.9 | 5,878,004.57 | 53,215,053.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 59,175,336.21 | 32,699,755.78 | 13,253,728.51 | -69,493,156.45 |
| 加:投资收益 | 17,342,857.27 | -12,094,720.76 | -8,001,842.97 | -28,719,824.06 |
| 资产处置收益 | -2,695,052.37 | -14,072.93 | -14,072.93 | 2,333,721.93 |
| 资产减值损失(新) | -70,395,040.05 | -54,290,859.75 | -19,483,656.25 | -122,874,355.27 |
| 信用减值损失(新) | 4,119,100.99 | -12,582,431.39 | -10,774,825.17 | -36,583,575.06 |
| 其他收益 | 111,048,572.62 | 72,872,005.25 | 35,671,966.73 | 157,439,567.77 |
| 四、营业利润 | 555,157,968.34 | 541,255,245.22 | 376,768,523.14 | 1,470,788,599.09 |
| 加:营业外收入 | 12,636,565.55 | 9,974,467.76 | 686,062.23 | 9,954,857.48 |
| 减:营业外支出 | 18,637,791.5 | 8,368,739.51 | 2,442,285.13 | 17,134,981.62 |
| 五、利润总额 | 549,156,742.39 | 542,860,973.47 | 375,012,300.24 | 1,463,608,474.95 |
| 减:所得税费用 | 175,226,638.46 | 137,702,111.93 | 78,972,621.92 | 356,145,358.12 |
| 六、净利润 | 373,930,103.93 | 405,158,861.54 | 296,039,678.32 | 1,107,463,116.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 373,930,103.93 | 405,158,861.54 | 296,039,678.32 | 1,107,463,116.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 380,356,337.29 | 409,487,616.19 | 297,404,077.75 | 1,118,981,177.61 |
| 少数股东损益 | -6,426,233.36 | -4,328,754.65 | -1,364,399.43 | -11,518,060.78 |
| 扣除非经常损益后的净利润 | 270,050,885.01 | 363,424,637.01 | 284,527,417.52 | 1,129,321,710.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.26 | 0.28 | 0.21 | 0.77 |
| (二)稀释每股收益 | 0.26 | 0.28 | 0.21 | 0.77 |
| 八、其他综合收益 | -343,912.19 | 2,468,726.33 | 739,654.29 | -110,875.97 |
| 归属于母公司股东的其他综合收益 | -438,740.6 | 2,434,094.49 | 727,805.31 | -20,149.96 |
| 九、综合收益总额 | 373,586,191.74 | 407,627,587.87 | 296,779,332.61 | 1,107,352,240.86 |
| 归属于母公司股东的综合收益总额 | 379,917,596.69 | 411,921,710.68 | 298,131,883.06 | 1,118,961,027.65 |
| 归属于少数股东的综合收益总额 | -6,331,404.95 | -4,294,122.81 | -1,352,550.45 | -11,608,786.79 |
| 公告日期 | 2025-10-31 | 2025-08-26 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |